Updated July 29, 2026, 12:21 pm EDT / Original July 29, 2026, 6:02 am EDT
As revenue continues to fall within Biogen’s
BIIB
-0.62%
market-leading
multiple sclerosis franchise
, the company is leaning on a handful of other drugs to drive growth. The strategy appears to be working.
BIIB
-0.62%
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

#company #jones #rights